Ellis Sean 4

What Happened

• Sean Ellis, a director of Entera Bio Ltd. (ENTX), reported an open-market purchase of 10,000 common shares on 2026-03-05. The reported weighted-average price was $1.23 per share, for a total cost of approximately $12,300. This was a straight purchase (Transaction code: P).

Key Details

• Transaction date: 2026-03-05; Filing date: 2026-03-09 (filed within the standard two-business-day Form 4 window).
• Reported price: weighted average $1.23; actual execution prices ranged from $1.2287 to $1.245 (see footnote).
• Shares acquired: 10,000; total reported value ≈ $12,300.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote: The $1.23 figure is a weighted average; the reporting person will provide a breakdown of the number of shares bought at each price in the $1.2287–$1.245 range upon request.
• No 10b5-1 trading plan, option exercise, gift, or tax-withholding transaction was disclosed in the filing excerpt.

Context

• This is a direct open-market purchase by a company director. The dollar amount is relatively small ($12.3k), so while insider purchases are often watched by investors, this single, modest buy should be viewed as a routine insider purchase rather than a definitive signal about company valuation or prospects.